nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—STK10—renal vein—nephrolithiasis	0.109	0.214	CbGeAlD
Vandetanib—STK10—renal artery—nephrolithiasis	0.0733	0.144	CbGeAlD
Vandetanib—Conduction disorder—Hydrochlorothiazide—nephrolithiasis	0.0361	0.116	CcSEcCtD
Vandetanib—RET—parathyroid gland—nephrolithiasis	0.0315	0.062	CbGeAlD
Vandetanib—Blood potassium increased—Hydrochlorothiazide—nephrolithiasis	0.025	0.0805	CcSEcCtD
Vandetanib—FMO3—urine—nephrolithiasis	0.0238	0.0468	CbGeAlD
Vandetanib—Serum creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0395	CcSEcCtD
Vandetanib—PTK6—renal system—nephrolithiasis	0.0114	0.0225	CbGeAlD
Vandetanib—Ventricular arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0328	CcSEcCtD
Vandetanib—Tubulointerstitial nephritis—Hydrochlorothiazide—nephrolithiasis	0.00987	0.0317	CcSEcCtD
Vandetanib—RIPK2—nephron tubule—nephrolithiasis	0.00748	0.0147	CbGeAlD
Vandetanib—VEGFA—nephron tubule—nephrolithiasis	0.00746	0.0147	CbGeAlD
Vandetanib—FMO1—nephron tubule—nephrolithiasis	0.00742	0.0146	CbGeAlD
Vandetanib—ERBB3—nephron tubule—nephrolithiasis	0.00716	0.0141	CbGeAlD
Vandetanib—FMO1—renal system—nephrolithiasis	0.00674	0.0132	CbGeAlD
Vandetanib—FMO1—kidney—nephrolithiasis	0.00652	0.0128	CbGeAlD
Vandetanib—ERBB3—renal system—nephrolithiasis	0.0065	0.0128	CbGeAlD
Vandetanib—FLT4—cortex of kidney—nephrolithiasis	0.00643	0.0126	CbGeAlD
Vandetanib—VEGFA—cortex of kidney—nephrolithiasis	0.00638	0.0125	CbGeAlD
Vandetanib—SLK—nephron tubule—nephrolithiasis	0.00636	0.0125	CbGeAlD
Vandetanib—FMO1—cortex of kidney—nephrolithiasis	0.00635	0.0125	CbGeAlD
Vandetanib—ERBB3—kidney—nephrolithiasis	0.00629	0.0124	CbGeAlD
Vandetanib—CYP3A4—urine—nephrolithiasis	0.00622	0.0122	CbGeAlD
Vandetanib—Gastroenteritis—Hydrochlorothiazide—nephrolithiasis	0.00619	0.0199	CcSEcCtD
Vandetanib—FYN—nephron tubule—nephrolithiasis	0.00619	0.0122	CbGeAlD
Vandetanib—RET—renal system—nephrolithiasis	0.00603	0.0119	CbGeAlD
Vandetanib—RET—kidney—nephrolithiasis	0.00583	0.0115	CbGeAlD
Vandetanib—Atrial fibrillation—Hydrochlorothiazide—nephrolithiasis	0.00579	0.0186	CcSEcCtD
Vandetanib—MKNK1—cortex of kidney—nephrolithiasis	0.00575	0.0113	CbGeAlD
Vandetanib—AXL—cortex of kidney—nephrolithiasis	0.00566	0.0111	CbGeAlD
Vandetanib—FYN—renal system—nephrolithiasis	0.00562	0.0111	CbGeAlD
Vandetanib—YES1—nephron tubule—nephrolithiasis	0.00558	0.011	CbGeAlD
Vandetanib—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.00551	0.0177	CcSEcCtD
Vandetanib—TEK—renal system—nephrolithiasis	0.0055	0.0108	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Hydrochlorothiazide—nephrolithiasis	0.00548	0.0176	CcSEcCtD
Vandetanib—SLK—cortex of kidney—nephrolithiasis	0.00545	0.0107	CbGeAlD
Vandetanib—FYN—kidney—nephrolithiasis	0.00544	0.0107	CbGeAlD
Vandetanib—TEK—kidney—nephrolithiasis	0.00531	0.0104	CbGeAlD
Vandetanib—FYN—cortex of kidney—nephrolithiasis	0.00529	0.0104	CbGeAlD
Vandetanib—TEK—cortex of kidney—nephrolithiasis	0.00517	0.0102	CbGeAlD
Vandetanib—MAP4K5—cortex of kidney—nephrolithiasis	0.00517	0.0102	CbGeAlD
Vandetanib—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.00514	0.0165	CcSEcCtD
Vandetanib—YES1—renal system—nephrolithiasis	0.00508	0.00997	CbGeAlD
Vandetanib—STK10—renal system—nephrolithiasis	0.00503	0.00988	CbGeAlD
Vandetanib—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.00503	0.0162	CcSEcCtD
Vandetanib—Hypokalaemia—Hydrochlorothiazide—nephrolithiasis	0.00499	0.0161	CcSEcCtD
Vandetanib—EPHB6—cortex of kidney—nephrolithiasis	0.00494	0.00972	CbGeAlD
Vandetanib—KDR—nephron tubule—nephrolithiasis	0.00494	0.00971	CbGeAlD
Vandetanib—YES1—kidney—nephrolithiasis	0.00491	0.00964	CbGeAlD
Vandetanib—SRC—renal system—nephrolithiasis	0.00488	0.00959	CbGeAlD
Vandetanib—STK10—kidney—nephrolithiasis	0.00486	0.00955	CbGeAlD
Vandetanib—Gastritis—Hydrochlorothiazide—nephrolithiasis	0.00485	0.0156	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.00484	0.0156	CcSEcCtD
Vandetanib—YES1—cortex of kidney—nephrolithiasis	0.00478	0.00939	CbGeAlD
Vandetanib—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.00474	0.0152	CcSEcCtD
Vandetanib—Influenza—Hydrochlorothiazide—nephrolithiasis	0.00474	0.0152	CcSEcCtD
Vandetanib—SRC—kidney—nephrolithiasis	0.00472	0.00928	CbGeAlD
Vandetanib—Pancreatitis—Hydrochlorothiazide—nephrolithiasis	0.00465	0.0149	CcSEcCtD
Vandetanib—KDR—renal system—nephrolithiasis	0.00449	0.00883	CbGeAlD
Vandetanib—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.00443	0.0143	CcSEcCtD
Vandetanib—Neutropenia—Hydrochlorothiazide—nephrolithiasis	0.00443	0.0143	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Hydrochlorothiazide—nephrolithiasis	0.00441	0.0142	CcSEcCtD
Vandetanib—Pollakiuria—Hydrochlorothiazide—nephrolithiasis	0.00438	0.0141	CcSEcCtD
Vandetanib—KDR—kidney—nephrolithiasis	0.00434	0.00853	CbGeAlD
Vandetanib—Photosensitivity reaction—Hydrochlorothiazide—nephrolithiasis	0.00433	0.0139	CcSEcCtD
Vandetanib—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.00428	0.0138	CcSEcCtD
Vandetanib—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.00425	0.0137	CcSEcCtD
Vandetanib—KDR—cortex of kidney—nephrolithiasis	0.00423	0.00831	CbGeAlD
Vandetanib—MAP2K5—cortex of kidney—nephrolithiasis	0.00423	0.00831	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Hydrochlorothiazide—nephrolithiasis	0.00419	0.0135	CcSEcCtD
Vandetanib—Renal failure—Hydrochlorothiazide—nephrolithiasis	0.00415	0.0134	CcSEcCtD
Vandetanib—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.00411	0.0132	CcSEcCtD
Vandetanib—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.00411	0.0132	CcSEcCtD
Vandetanib—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.00403	0.013	CcSEcCtD
Vandetanib—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.00399	0.0128	CcSEcCtD
Vandetanib—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.00397	0.0128	CcSEcCtD
Vandetanib—PDGFRB—renal system—nephrolithiasis	0.00389	0.00764	CbGeAlD
Vandetanib—Bradycardia—Hydrochlorothiazide—nephrolithiasis	0.00386	0.0124	CcSEcCtD
Vandetanib—ABL1—nephron tubule—nephrolithiasis	0.00381	0.00749	CbGeAlD
Vandetanib—PDGFRB—kidney—nephrolithiasis	0.00376	0.00738	CbGeAlD
Vandetanib—PDGFRB—cortex of kidney—nephrolithiasis	0.00366	0.00719	CbGeAlD
Vandetanib—Visual impairment—Hydrochlorothiazide—nephrolithiasis	0.00366	0.0118	CcSEcCtD
Vandetanib—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00359	0.0115	CcSEcCtD
Vandetanib—ABL1—renal system—nephrolithiasis	0.00346	0.00681	CbGeAlD
Vandetanib—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00339	0.0109	CcSEcCtD
Vandetanib—Alopecia—Hydrochlorothiazide—nephrolithiasis	0.00335	0.0108	CcSEcCtD
Vandetanib—ABL1—kidney—nephrolithiasis	0.00335	0.00658	CbGeAlD
Vandetanib—ABL1—cortex of kidney—nephrolithiasis	0.00326	0.00641	CbGeAlD
Vandetanib—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00323	0.0104	CcSEcCtD
Vandetanib—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00318	0.0102	CcSEcCtD
Vandetanib—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00311	0.01	CcSEcCtD
Vandetanib—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00309	0.00995	CcSEcCtD
Vandetanib—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.0029	0.00934	CcSEcCtD
Vandetanib—Cough—Hydrochlorothiazide—nephrolithiasis	0.00288	0.00927	CcSEcCtD
Vandetanib—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00905	CcSEcCtD
Vandetanib—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00281	0.00905	CcSEcCtD
Vandetanib—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.0028	0.00901	CcSEcCtD
Vandetanib—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00275	0.00885	CcSEcCtD
Vandetanib—Oedema—Hydrochlorothiazide—nephrolithiasis	0.0027	0.00867	CcSEcCtD
Vandetanib—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.00264	0.00849	CcSEcCtD
Vandetanib—ABCC1—cortex of kidney—nephrolithiasis	0.00248	0.00488	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00246	0.0079	CcSEcCtD
Vandetanib—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00244	0.00784	CcSEcCtD
Vandetanib—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00242	0.00779	CcSEcCtD
Vandetanib—ABCG2—nephron tubule—nephrolithiasis	0.0024	0.00472	CbGeAlD
Vandetanib—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.0024	0.00773	CcSEcCtD
Vandetanib—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00237	0.00763	CcSEcCtD
Vandetanib—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00234	0.00754	CcSEcCtD
Vandetanib—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.00232	0.00748	CcSEcCtD
Vandetanib—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00741	CcSEcCtD
Vandetanib—Pain—Hydrochlorothiazide—nephrolithiasis	0.00231	0.00741	CcSEcCtD
Vandetanib—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0022	0.00709	CcSEcCtD
Vandetanib—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00213	0.00685	CcSEcCtD
Vandetanib—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00213	0.00685	CcSEcCtD
Vandetanib—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00193	0.00622	CcSEcCtD
Vandetanib—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00191	0.00613	CcSEcCtD
Vandetanib—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00184	0.00593	CcSEcCtD
Vandetanib—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00178	0.00573	CcSEcCtD
Vandetanib—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00171	0.00551	CcSEcCtD
Vandetanib—Rash—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00547	CcSEcCtD
Vandetanib—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.0017	0.00546	CcSEcCtD
Vandetanib—Headache—Hydrochlorothiazide—nephrolithiasis	0.00169	0.00543	CcSEcCtD
Vandetanib—Nausea—Hydrochlorothiazide—nephrolithiasis	0.0016	0.00515	CcSEcCtD
Vandetanib—CYP3A4—renal system—nephrolithiasis	0.00152	0.00299	CbGeAlD
Vandetanib—CYP3A4—kidney—nephrolithiasis	0.00147	0.00289	CbGeAlD
Vandetanib—FMO1—Metabolism—GRHPR—nephrolithiasis	0.000849	0.00471	CbGpPWpGaD
Vandetanib—LCK—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000827	0.00459	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—RGS14—nephrolithiasis	0.000812	0.00451	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000794	0.0044	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000794	0.0044	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—ADCY10—nephrolithiasis	0.000792	0.00439	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—AGXT—nephrolithiasis	0.000757	0.0042	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC26A6—nephrolithiasis	0.000756	0.00419	CbGpPWpGaD
Vandetanib—SRC—FGF signaling pathway—SPP1—nephrolithiasis	0.000751	0.00416	CbGpPWpGaD
Vandetanib—MAP2K5—BDNF signaling pathway—SPP1—nephrolithiasis	0.000748	0.00415	CbGpPWpGaD
Vandetanib—SRC—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000732	0.00406	CbGpPWpGaD
Vandetanib—MKNK1—Disease—SLC26A1—nephrolithiasis	0.000729	0.00404	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—SLC7A9—nephrolithiasis	0.000722	0.00401	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—DGKH—nephrolithiasis	0.000722	0.00401	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000708	0.00393	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000699	0.00388	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000699	0.00388	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—DGKH—nephrolithiasis	0.000698	0.00387	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—SLC7A9—nephrolithiasis	0.000698	0.00387	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC3A1—nephrolithiasis	0.000691	0.00384	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC34A3—nephrolithiasis	0.000691	0.00384	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—RGS14—nephrolithiasis	0.000673	0.00374	CbGpPWpGaD
Vandetanib—SRC—Integrins in angiogenesis—SPP1—nephrolithiasis	0.000663	0.00368	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—DGKH—nephrolithiasis	0.000656	0.00364	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000656	0.00364	CbGpPWpGaD
Vandetanib—MKNK1—Disease—ATP6V0A4—nephrolithiasis	0.000649	0.0036	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000647	0.00359	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000647	0.00359	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—APRT—nephrolithiasis	0.000644	0.00357	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—SLC26A1—nephrolithiasis	0.000644	0.00357	CbGpPWpGaD
Vandetanib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—CHRM3—nephrolithiasis	0.000634	0.00352	CbGpPWpGaD
Vandetanib—BLK—Focal Adhesion—SPP1—nephrolithiasis	0.00063	0.0035	CbGpPWpGaD
Vandetanib—FGR—Focal Adhesion—SPP1—nephrolithiasis	0.000628	0.00349	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000623	0.00345	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—GRHPR—nephrolithiasis	0.000607	0.00337	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.0006	0.00333	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—DGKH—nephrolithiasis	0.0006	0.00333	CbGpPWpGaD
Vandetanib—MAP2K5—Focal Adhesion—SPP1—nephrolithiasis	0.000599	0.00333	CbGpPWpGaD
Vandetanib—ERBB3—Signaling by PDGF—SPP1—nephrolithiasis	0.000598	0.00332	CbGpPWpGaD
Vandetanib—KDR—Focal Adhesion—SPP1—nephrolithiasis	0.000584	0.00324	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000569	0.00316	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000569	0.00316	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000549	0.00305	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—DGKH—nephrolithiasis	0.000549	0.00305	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AGXT—nephrolithiasis	0.000541	0.003	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—ADCY10—nephrolithiasis	0.000532	0.00295	CbGpPWpGaD
Vandetanib—VEGFA—Focal Adhesion—SPP1—nephrolithiasis	0.000525	0.00291	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC34A1—nephrolithiasis	0.000524	0.00291	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC22A12—nephrolithiasis	0.000524	0.00291	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—DGKH—nephrolithiasis	0.00052	0.00289	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—SLC7A9—nephrolithiasis	0.00052	0.00289	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—SLC7A9—nephrolithiasis	0.000518	0.00287	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—DGKH—nephrolithiasis	0.000518	0.00287	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—DGKH—nephrolithiasis	0.000512	0.00284	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—SLC7A9—nephrolithiasis	0.000512	0.00284	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—DGKH—nephrolithiasis	0.000494	0.00274	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.00049	0.00272	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.00049	0.00272	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC26A1—nephrolithiasis	0.000487	0.0027	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC2A9—nephrolithiasis	0.000487	0.0027	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ADCY10—nephrolithiasis	0.000487	0.0027	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ADCY10—nephrolithiasis	0.000474	0.00263	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—CHRM3—nephrolithiasis	0.000474	0.00263	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ADCY10—nephrolithiasis	0.000469	0.0026	CbGpPWpGaD
Vandetanib—FYN—BDNF signaling pathway—SPP1—nephrolithiasis	0.000465	0.00258	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—SLC26A1—nephrolithiasis	0.00046	0.00255	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—APRT—nephrolithiasis	0.00046	0.00255	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—AQP1—nephrolithiasis	0.000459	0.00254	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000456	0.00253	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000456	0.00253	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000455	0.00252	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—DGKH—nephrolithiasis	0.000455	0.00252	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—RGS14—nephrolithiasis	0.000452	0.00251	CbGpPWpGaD
Vandetanib—KDR—Extracellular matrix organization—SPP1—nephrolithiasis	0.000449	0.00249	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC7A9—nephrolithiasis	0.000434	0.00241	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—PTH—nephrolithiasis	0.000434	0.00241	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—CHRM3—nephrolithiasis	0.000434	0.00241	CbGpPWpGaD
Vandetanib—ERBB3—Disease—SLC26A1—nephrolithiasis	0.000432	0.0024	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000432	0.00239	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000432	0.00239	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—CLCN4—nephrolithiasis	0.000431	0.00239	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—CLCN5—nephrolithiasis	0.000431	0.00239	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—SLC7A9—nephrolithiasis	0.000426	0.00237	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—DGKH—nephrolithiasis	0.000426	0.00237	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ADCY10—nephrolithiasis	0.000426	0.00237	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—CHRM3—nephrolithiasis	0.000415	0.0023	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—RGS14—nephrolithiasis	0.000414	0.0023	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ADCY10—nephrolithiasis	0.000412	0.00229	CbGpPWpGaD
Vandetanib—EGFR—Direct p53 effectors—SPP1—nephrolithiasis	0.000411	0.00228	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000406	0.00225	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000406	0.00225	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RGS14—nephrolithiasis	0.000403	0.00224	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000401	0.00223	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000401	0.00223	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by PDGF—SPP1—nephrolithiasis	0.0004	0.00222	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RGS14—nephrolithiasis	0.000399	0.00221	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—PTH—nephrolithiasis	0.000397	0.0022	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—CHRM3—nephrolithiasis	0.000397	0.0022	CbGpPWpGaD
Vandetanib—PDGFRB—Focal Adhesion—SPP1—nephrolithiasis	0.000386	0.00214	CbGpPWpGaD
Vandetanib—FYN—Signaling by PDGF—SPP1—nephrolithiasis	0.000385	0.00214	CbGpPWpGaD
Vandetanib—ERBB3—Disease—ATP6V0A4—nephrolithiasis	0.000385	0.00214	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC26A6—nephrolithiasis	0.000384	0.00213	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—SLC7A9—nephrolithiasis	0.000377	0.00209	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—DGKH—nephrolithiasis	0.000377	0.00209	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—RGS14—nephrolithiasis	0.000376	0.00209	CbGpPWpGaD
Vandetanib—FYN—Focal Adhesion—SPP1—nephrolithiasis	0.000372	0.00207	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—SLC26A1—nephrolithiasis	0.000366	0.00203	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—PTH—nephrolithiasis	0.000363	0.00201	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RGS14—nephrolithiasis	0.000362	0.00201	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000358	0.00198	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000358	0.00198	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC34A3—nephrolithiasis	0.000351	0.00195	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC3A1—nephrolithiasis	0.000351	0.00195	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RGS14—nephrolithiasis	0.00035	0.00194	CbGpPWpGaD
Vandetanib—SRC—BDNF signaling pathway—SPP1—nephrolithiasis	0.000342	0.0019	CbGpPWpGaD
Vandetanib—EGFR—Signaling by PDGF—SPP1—nephrolithiasis	0.000333	0.00185	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—CHRM3—nephrolithiasis	0.000329	0.00182	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—AQP1—nephrolithiasis	0.000328	0.00182	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000325	0.0018	CbGpPWpGaD
Vandetanib—EGFR—Focal Adhesion—SPP1—nephrolithiasis	0.000322	0.00178	CbGpPWpGaD
Vandetanib—LCK—Signaling by PDGF—SPP1—nephrolithiasis	0.000321	0.00178	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ADCY10—nephrolithiasis	0.000314	0.00174	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ADCY10—nephrolithiasis	0.000307	0.0017	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000306	0.0017	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DGKH—nephrolithiasis	0.000306	0.0017	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ADCY10—nephrolithiasis	0.000302	0.00168	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—PTH—nephrolithiasis	0.000301	0.00167	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—CHRM3—nephrolithiasis	0.000296	0.00165	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SLC26A1—nephrolithiasis	0.000289	0.0016	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000286	0.00159	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—SPP1—nephrolithiasis	0.000284	0.00158	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GRHPR—nephrolithiasis	0.000282	0.00156	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DGKH—nephrolithiasis	0.00028	0.00155	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00028	0.00155	CbGpPWpGaD
Vandetanib—FYN—Disease—SLC26A1—nephrolithiasis	0.000278	0.00154	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—SPP1—nephrolithiasis	0.000274	0.00152	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000272	0.00151	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DGKH—nephrolithiasis	0.000272	0.00151	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000269	0.0015	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DGKH—nephrolithiasis	0.000269	0.0015	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RGS14—nephrolithiasis	0.000267	0.00148	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC34A1—nephrolithiasis	0.000266	0.00148	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC22A12—nephrolithiasis	0.000266	0.00148	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADCY10—nephrolithiasis	0.000261	0.00145	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RGS14—nephrolithiasis	0.000261	0.00145	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—ATP6V0A4—nephrolithiasis	0.000257	0.00143	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RGS14—nephrolithiasis	0.000257	0.00143	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SLC26A1—nephrolithiasis	0.000255	0.00141	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—DGKH—nephrolithiasis	0.000255	0.00141	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—SLC7A9—nephrolithiasis	0.000255	0.00141	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DGKH—nephrolithiasis	0.000254	0.00141	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADCY10—nephrolithiasis	0.000252	0.0014	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AGXT—nephrolithiasis	0.000251	0.00139	CbGpPWpGaD
Vandetanib—FYN—Disease—ATP6V0A4—nephrolithiasis	0.000248	0.00138	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GRHPR—nephrolithiasis	0.000248	0.00138	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC2A9—nephrolithiasis	0.000248	0.00137	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC26A1—nephrolithiasis	0.000248	0.00137	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000245	0.00136	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DGKH—nephrolithiasis	0.000245	0.00136	CbGpPWpGaD
Vandetanib—EGFR—Disease—SLC26A1—nephrolithiasis	0.00024	0.00133	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DGKH—nephrolithiasis	0.000237	0.00131	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000237	0.00131	CbGpPWpGaD
Vandetanib—LCK—Disease—SLC26A1—nephrolithiasis	0.000232	0.00129	CbGpPWpGaD
Vandetanib—ABCC1—Disease—ATP6V0A4—nephrolithiasis	0.000227	0.00126	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADCY10—nephrolithiasis	0.000223	0.00124	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RGS14—nephrolithiasis	0.000222	0.00123	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AGXT—nephrolithiasis	0.000221	0.00123	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CHRM3—nephrolithiasis	0.000221	0.00123	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—ATP6V0A4—nephrolithiasis	0.000221	0.00122	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC7A9—nephrolithiasis	0.000221	0.00122	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—SPP1—nephrolithiasis	0.000218	0.00121	CbGpPWpGaD
Vandetanib—EGFR—Disease—ATP6V0A4—nephrolithiasis	0.000214	0.00119	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RGS14—nephrolithiasis	0.000214	0.00119	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—APRT—nephrolithiasis	0.000214	0.00118	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—SLC26A1—nephrolithiasis	0.000214	0.00118	CbGpPWpGaD
Vandetanib—LCK—Disease—ATP6V0A4—nephrolithiasis	0.000206	0.00115	CbGpPWpGaD
Vandetanib—SRC—Disease—SLC26A1—nephrolithiasis	0.000205	0.00114	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—PTH—nephrolithiasis	0.000202	0.00112	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CHRM3—nephrolithiasis	0.000202	0.00112	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—SPP1—nephrolithiasis	0.000199	0.00111	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CHRM3—nephrolithiasis	0.000197	0.00109	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CHRM3—nephrolithiasis	0.000195	0.00108	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RGS14—nephrolithiasis	0.000189	0.00105	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—SLC26A1—nephrolithiasis	0.000188	0.00104	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—APRT—nephrolithiasis	0.000188	0.00104	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PTH—nephrolithiasis	0.000185	0.00103	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CHRM3—nephrolithiasis	0.000184	0.00102	CbGpPWpGaD
Vandetanib—SRC—Disease—ATP6V0A4—nephrolithiasis	0.000183	0.00101	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—SPP1—nephrolithiasis	0.000182	0.00101	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PTH—nephrolithiasis	0.00018	0.001	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00018	0.001	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DGKH—nephrolithiasis	0.00018	0.001	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PTH—nephrolithiasis	0.000178	0.000989	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CHRM3—nephrolithiasis	0.000177	0.000982	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—AQP1—nephrolithiasis	0.000176	0.000979	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000176	0.000979	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DGKH—nephrolithiasis	0.000176	0.000979	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DGKH—nephrolithiasis	0.000174	0.000963	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000174	0.000963	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CHRM3—nephrolithiasis	0.000171	0.000949	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PTH—nephrolithiasis	0.000168	0.000932	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PTH—nephrolithiasis	0.000162	0.000898	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PTH—nephrolithiasis	0.000156	0.000868	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GRHPR—nephrolithiasis	0.000153	0.000849	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AQP1—nephrolithiasis	0.000152	0.000844	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—SPP1—nephrolithiasis	0.000151	0.000838	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.00015	0.000832	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DGKH—nephrolithiasis	0.00015	0.000832	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000145	0.000802	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DGKH—nephrolithiasis	0.000145	0.000802	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CHRM3—nephrolithiasis	0.000138	0.000764	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGXT—nephrolithiasis	0.000136	0.000757	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AQP1—nephrolithiasis	0.000134	0.000743	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CHRM3—nephrolithiasis	0.00013	0.000723	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ATP6V0A4—nephrolithiasis	0.000128	0.00071	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DGKH—nephrolithiasis	0.000128	0.00071	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CHRM3—nephrolithiasis	0.000128	0.000708	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CHRM3—nephrolithiasis	0.000126	0.000697	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CHRM3—nephrolithiasis	0.000121	0.000672	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PTH—nephrolithiasis	0.000119	0.000661	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PTH—nephrolithiasis	0.000117	0.000647	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC26A1—nephrolithiasis	0.000116	0.000643	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APRT—nephrolithiasis	0.000116	0.000643	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PTH—nephrolithiasis	0.000115	0.000637	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CHRM3—nephrolithiasis	0.000108	0.000602	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CHRM3—nephrolithiasis	0.000105	0.00058	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—SPP1—nephrolithiasis	0.000101	0.000563	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PTH—nephrolithiasis	9.92e-05	0.00055	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PTH—nephrolithiasis	9.56e-05	0.00053	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—SPP1—nephrolithiasis	9.28e-05	0.000515	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CHRM3—nephrolithiasis	9.25e-05	0.000513	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SPP1—nephrolithiasis	9.04e-05	0.000502	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SPP1—nephrolithiasis	8.94e-05	0.000496	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTH—nephrolithiasis	8.46e-05	0.00047	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AQP1—nephrolithiasis	8.26e-05	0.000458	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GRHPR—nephrolithiasis	8.26e-05	0.000458	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SPP1—nephrolithiasis	8.13e-05	0.000451	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SPP1—nephrolithiasis	7.85e-05	0.000436	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CHRM3—nephrolithiasis	7.47e-05	0.000415	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGXT—nephrolithiasis	7.36e-05	0.000408	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC26A1—nephrolithiasis	6.26e-05	0.000347	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APRT—nephrolithiasis	6.26e-05	0.000347	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SPP1—nephrolithiasis	5.98e-05	0.000332	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SPP1—nephrolithiasis	5.85e-05	0.000325	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SPP1—nephrolithiasis	5.76e-05	0.00032	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SPP1—nephrolithiasis	4.98e-05	0.000276	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SPP1—nephrolithiasis	4.8e-05	0.000266	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AQP1—nephrolithiasis	4.46e-05	0.000247	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SPP1—nephrolithiasis	4.25e-05	0.000236	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CHRM3—nephrolithiasis	4.03e-05	0.000224	CbGpPWpGaD
